Sector News

BMS to invest in new cell therapy manufacturing site in Europe

April 25, 2021
Life sciences

Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.

In a statement, BMS said that the new site would tap into the growing life sciences region near Amsterdam, as well as the ‘convenient access’ to transportation for shipping patient cells.

The new investment will expand BMS’ global manufacturing capacity for its cell therapy franchise, which includes the recently approved CAR T therapies Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).

The Leiden site will become BMS’ fifth cell therapy manufacturing facility, and the company’s first in Europe.

It will be commercially focused, BMS added, with additional capabilities for multi-product cell therapy manufacturing and the ability to scale up capacity.

BMS said that the site will leverage ‘innovative’ technologies, while also utilising the latest manufacturing equipment and advanced digital systems.

“A key element of BMS’ commitment to cell therapy is our continuous investment in advanced manufacturing capabilities, from the expansion of our global network and capacity to treat patients to reduced turn around time and optimised costs,” said Ann Lee, senior vice president, cell therapy development & operations, BMS.

“We continue to grow our presence in Europe and the Netherlands, which offers an innovative life sciences hub and world class industry talent, and we look forward to hiring several hundred talented people over the coming years to join our global team and participate in our cell therapy journey,” she added.

The site design and development planning for the site is currently underway, with BMS anticipating construction to begin later this year.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.